ImmunoGen, Inc. (IMGN) Q4 2021 Earnings Conference Call February 24, 2022 8:00 AM ET
Company Participants
Courtney O'Konek - Senior Director, Corporate Communications & Investor Relations
Mark Enyedy - President & Chief Executive Officer
Anna Berkenblit - Chief Medical Officer
Susan Altschuller - Chief Financial Officer
Kristen Smith - Chief Commercial Officer
Conference Call Participants
John Newman - Canaccord Genuity
Yige Guo - Guggenheim Securities
Etzer Darout - BMO Capital Markets
Boris Peaker - Cowen
Andy Hsieh - William Blair & Company
Kennan MacKay - RBC Capital Markets
Jessica Fye - JPMorgan
Earl DeSouza - H.C. Wainwright
Joseph Catanzaro - Piper Sandler
Jonathan Chang - SVB Leerink
Operator
Good morning, ladies and gentlemen and welcome to ImmunoGen's Fourth Quarter and Full Year 2021 Financial and Operating Results Conference Call. Today's conference is being recorded.
At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications. Please go ahead.
Courtney O'Konek
Good morning and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent progress and fourth quarter and full year 2021 financial results. This press release and a recording of this call can be found under the Investors and Media section of our website at immunogen.com. With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO; Kristen Smith, our Chief Commercial Officer will also join us for Q&A.
During today's call, we will review recent accomplishments for the business, our financial results and highlight upcoming anticipated events. We will use forward-looking statements with respect to our business strategy, the development and benefit of our product candidates, the design of our clinical trials, the presentation of clinical trial data for our product candidates, the anticipated timing of clinical trials and
- Read more current IMGN analysis and news
- View all earnings call transcripts